| 3.32 -0.005 (-0.15%) | 12-05 10:02 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.02  |
1-year : | 4.7 |
| Resists | First : | 3.45 |
Second : | 4.02 |
| Pivot price | 2.98 |
|||
| Supports | First : | 2.93 |
Second : | 2.6 |
| MAs | MA(5) : | 3.13 |
MA(20) : | 3 |
| MA(100) : | 2.85 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.1 |
D(3) : | 60.7 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 4.98 | Low : | 1.14 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SAVA ] has closed below upper band by 13.8%. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.35 - 3.37 | 3.37 - 3.38 |
| Low: | 3.02 - 3.04 | 3.04 - 3.06 |
| Close: | 3.29 - 3.32 | 3.32 - 3.35 |
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Wed, 03 Dec 2025
Cassava Sciences Inc - FDA requires additional information from Cassava for clinical study - SEC filing - marketscreener.com
Wed, 03 Dec 2025
Cassava Sciences Inc - FDA Requires Additional Information From Cassava For Clinical Study - SEC Filing - TradingView
Wed, 03 Dec 2025
Cassava Sciences hit with FDA request for more data on simufilam trial (SAVA:NASDAQ) - Seeking Alpha
Wed, 03 Dec 2025
Cassava Sciences Receives FDA Request for Additional Information - TradingView
Wed, 03 Dec 2025
Cassava Sciences receives FDA request for more information on epilepsy trial - Investing.com
Fri, 21 Nov 2025
Cassava Sciences (NASDAQ:SAVA) CEO Purchases $201,808.75 in Stock - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 12.7 (%) |
| Held by Institutions | 28.8 (%) |
| Shares Short | 7,320 (K) |
| Shares Short P.Month | 6,840 (K) |
| EPS | -2.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.69 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.8 % |
| Return on Equity (ttm) | -85.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.9 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -84 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -1.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.93 |
| Dividend | 5.25 |
| Forward Dividend | 0 |
| Dividend Yield | 157.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|